Najat Khan, Chief Commercial Officer at The Janssen Pharmaceutical Companies and board member at Recursion, shared a post on LinkedIn:
“Yesterday I took the stage at JPM 2026 to share where Recursion is today and, even more importantly, where we’re going next.
Our recent momentum and our path ahead make this a very exciting time for Recursion. My message is straightforward: this is the moment we move from insights to proof points. That means translating ideas into medicines, innovating with intention, and matching bold ambition with real discipline.
- First: turning insights into proof points – and ultimately medicines.
We are now demonstrating that AI-identified biology can translate into meaningful clinical outcomes. Our FAP program is a clear example. A novel platform insight identifying MEK1/2 inhibition as a new therapeutic entry point has become a potential therapy that is driving rapid and durable reductions in polyp burden for patients with a disease that has no approved treatments. It’s one of the clear signals of platform validation: impact in the clinic.
This is the bar we are setting across our portfolio. We are focused on building unequivocal evidence that we can repeatedly turn scientific insight into medicines that matter, across both our internal programs and through our partnerships.
- Second: surgically doubling down on where we can strategically leverage our platform to solve major bottlenecks in R&D and drive real impact.
At Recursion, we’ve built a true end-to-end AI platform from idea to clinic, and we will continue to invest where it creates real value – where AI can improve the speed, probability of success, and confidence of decisions, from uncovering novel biology, to designing differentiated molecules, to running smarter, faster clinical trials.
- Third: pairing bold ambition with discipline – across execution, financial stewardship, and how we operate.
Ambition alone is not enough. Execution matters. That means making clear choices, applying rigorous go/no-go decisions, and allocating capital where we have a true competitive advantage. When ambition and discipline advance together, that’s when value truly compounds to build an iconic company that drives impact for patients.
What makes this all possible is our people and our One Recursion approach. We are united by our mission to radically improve lives and powered by our bilingual people. That means AI leaders who understand the complexity and humility needed to unlock medical breakthroughs, alongside scientists who understand the breakthrough potential of AI. Together, we’re connecting AI, biology, chemistry, and clinical development into a single engine – the first truly integrated AI-native platform – because that’s what’s needed to deliver differentiated medicines to patients who are waiting.
Grateful for the momentum we’re building and even more energized about what comes next.
Onwards!”
